| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07383441 Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer |
Recruitment opened |
| 2026-06-12 | NCT07383441 Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer |
Trial sites expanded: 0 -> 41 locations |
| 2026-06-06 | NCT05017012 A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC)… |
Trial completed |
| 2026-06-06 | NCT05017012 A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC)… |
Enrollment increased: 72 -> 142 participants |
| 2026-06-05 | NCT07227415 Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and… |
Trial sites expanded: 88 -> 109 locations |
| 2026-05-23 | NCT07227415 Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and… |
Trial sites expanded: 49 -> 88 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-05 | NCT07630363 PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | Phase 1/2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | Advanced Clear Cell Renal Cell Carcinoma | Recruiting |
| NCT05059522 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab… | Advanced Malignancies | Active, Not Recruiting |
| Phase 2 | |||
| NCT05384496 | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | Mucosal Melanoma | Recruiting |
| NCT07469683 | An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of… | Clear Cell Renal Cell Carcinoma | Recruiting |
| NCT07123090 | A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Recruiting |
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | Lymphoma, Non-Hodgkin | Recruiting |
| NCT05969496 | Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava… | Renal Cancer | Recruiting |
| NCT05327686 | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the… | Metastatic Renal Cell Carcinoma | Recruiting |
| NCT03839498 | Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in… | Pheochromocytoma | Active, Not Recruiting |
| NCT05805501 | A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With… | Renal Cell Carcinoma | Active, Not Recruiting |
| NCT03595124 | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal… | Metastatic Renal Cell Carcinoma | Active, Not Recruiting |
| NCT03092856 | Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With… | Clear Cell Renal Cell Carcinoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT07227415 | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and… | Carcinoma, Renal Cell | Recruiting |
| NCT05808608 | A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of… | Renal Cell Carcinoma | Active, Not Recruiting |
| NCT03172754 | Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma | Renal Cell Carcinoma | Active, Not Recruiting |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | Advanced Renal Cell Carcinoma (RCC) | Not Yet Recruiting |
| Phase 1 | |||
| NCT04693468 | Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or… | Advanced Malignant Solid Neoplasm | Recruiting |
| Not specified | |||
| NCT07500831 | Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With… | Carcinoma, Renal Cell | Not Yet Recruiting |